Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Michael R. Hayden bought 15,000 shares of the stock in a transaction on Monday, August 14th. The shares were acquired at an average cost of $2.75 per share, for a total transaction of $41,250.00. Following the completion of the transaction, the director now directly owns 161,187 shares of the company’s stock, valued at $443,264.25. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of Xenon Pharmaceuticals Inc. (XENE) traded down 1.698% during midday trading on Thursday, hitting $2.605. The stock had a trading volume of 12,657 shares. The company’s 50 day moving average price is $3.13 and its 200-day moving average price is $4.94. Xenon Pharmaceuticals Inc. has a 1-year low of $2.25 and a 1-year high of $9.95. The firm’s market capitalization is $46.88 million.
Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.03. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. Equities analysts predict that Xenon Pharmaceuticals Inc. will post ($0.96) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Xenon Pharmaceuticals Inc. (XENE) Director Acquires $41,250.00 in Stock” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/17/xenon-pharmaceuticals-inc-xene-director-acquires-41250-00-in-stock.html.
Several equities analysts have commented on XENE shares. Canaccord Genuity reissued a “buy” rating and set a $5.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Zacks Investment Research downgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Finally, Jefferies Group LLC set a $5.00 price target on Xenon Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $11.88.
Institutional investors have recently added to or reduced their stakes in the stock. Scotia Capital Inc. increased its position in Xenon Pharmaceuticals by 36.0% in the second quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 9,426 shares during the last quarter. Renaissance Technologies LLC increased its position in Xenon Pharmaceuticals by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 114,200 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 18,000 shares during the last quarter. KCG Holdings Inc. acquired a new position in Xenon Pharmaceuticals during the first quarter valued at about $122,000. DAFNA Capital Management LLC increased its position in Xenon Pharmaceuticals by 11.2% in the second quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 38,081 shares during the last quarter. Finally, K2 Principal Fund L.P. increased its position in Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock valued at $518,000 after buying an additional 47,535 shares during the last quarter. 56.01% of the stock is owned by hedge funds and other institutional investors.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
